Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

This study has been terminated.
(All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.)
Information provided by (Responsible Party):
Amgen Identifier:
First received: September 26, 2012
Last updated: January 18, 2016
Last verified: January 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2015
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 22, 2015